Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 USD | +0.91% | +0.45% | -0.89% |
Business Summary
Number of employees: 100
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Immunotherapies
100.0
%
| 6 | 100.0 % | 8 | 100.0 % | +37.48% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 8 | 100.0 % | +37.48% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 69 | 01/19/01 | |
William Quinn
DFI | Director of Finance/CFO | 53 | 01/20/01 |
John Tomaro
CTO | Chief Tech/Sci/R&D Officer | - | 01/20/01 |
Edith Perez
CTO | Chief Tech/Sci/R&D Officer | 67 | 01/20/01 |
Priti Hegde
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Karen L. Bergman
IRC | Investor Relations Contact | - | - |
Sarah Nemec
PRN | Corporate Officer/Principal | - | 01/20/01 |
Yu Tai
LAW | General Counsel | - | - |
Wesley Burwell
HRO | Human Resources Officer | - | 01/21/01 |
Grant Yonehiro
PRN | Corporate Officer/Principal | 60 | 01/16/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Miller
BRD | Director/Board Member | 73 | 01/17/01 |
Mahendra Shah
BRD | Director/Board Member | 79 | 01/16/01 |
James Healy
BRD | Director/Board Member | 58 | 01/21/01 |
Kathy LaPorte
BRD | Director/Board Member | 62 | 01/20/01 |
Edgar Engleman
FOU | Founder | 78 | 22/15/22 |
Nicole Onetto
BRD | Director/Board Member | 71 | 14/21/14 |
Director/Board Member | 54 | 17/21/17 | |
Chief Executive Officer | 69 | 01/19/01 | |
Frank Lee
BRD | Director/Board Member | 56 | 17/21/17 |
Laura Berner
BRD | Director/Board Member | 49 | 14/22/14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,127,740 | 36,624,368 ( 96.06 %) | 0 | 96.06 % |
Company contact information
Bolt Biotherapeutics, Inc.
900 Chesapeake Drive
94063, Redwood City
+650 665 9295
http://www.boltbio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.89% | 41.94M | |
+9.82% | 106B | |
+0.06% | 104B | |
+6.52% | 23.25B | |
-13.63% | 22.5B | |
-6.68% | 18.7B | |
-37.08% | 17.95B | |
-10.76% | 16.99B | |
+7.70% | 14.26B | |
+38.99% | 12.76B |
- Stock Market
- Equities
- BOLT Stock
- Company Bolt Biotherapeutics, Inc.